Based on a case we discussed the current treatment guidelines for essential thrombocythemia. Dr Spyridis presented the current How I treat Blood paper. Presenter: Dr Spyridis Participants: Prof: Spyridonidis, Dr Liga, Dr Aggelinas

We discussed a recent review of the Treatment Options for Carbapenem- Resistant Gram-Negative Infections. We additionally reviewed our current policy in treating these infections and implemented a new policy. Presenter: Prof. Marangos Participants: Prof. Spyridonidis, Dr Spyridis, Dr Liga, Dr Aggelinas.

We discussed novel insights regarding the pathophysiology of CRS after CART therapy published in Nature Medicine. Activation of macrophages plays a major role.

Goal: The Hellenic experience of the use of BV in relapsed HD was presented. The need for transplant after achieving some disease control was discussed. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.

Goal: We discussed the legislation about SEC and other terms such as GRID. The legislation was presented, especially the specific issue regarding BMT units in Greece which will be presented in EU TE Compenidum. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adopt this strategy. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To understand how PTCY works. We reviewed the current literature of PTCY after related or unrelated Tx. We discussed that the data are premature in order to adapt this strategy. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To present the analysis of our transplant strategy. Results of the analysis of about 100 transplants is shown. Dr Maria Liga presented us her database. Prof. Spyridonidis explained how the data were analysed. The decision to add Cellcept in the case of a...

Goal: The use of TKIs post transplant to prevent relapse. A recent paper describing how sorafenob in mflt3 mutant AML promotes the local GVL effect is presented.  Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: Our current research paper in CLL published in Blood Advances was presented. Further goals were discussed. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.

Goal: To learn how to calculate EFS,OS, TRM, how to create Kaplan Meier curves and CI curves. The difference between CI and Kapolan Meier was discussed. Corresponding literature from ALPWP EBMT is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.

Goal: To learn the differences between RIC, RTC, MAC, NMA, etc. Corresponding literature is provided. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: To learn how to deceide whether we should get an older person to transplant. Literature and cases are presented. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: To understand the structure of donor registries. Learn corresponding terminology. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal:To learn about Bite, inotuzumab and CART therapies. Presenter: Prof. Spyridonidis. Participants: Dr Liga, Dr Spyridis, Dr Aggelinas

Goal: Which graft is better to use in haplo PTCY transplant? Dr Liga presented the current literature. We deceide the following policy CR-1 BM, advanced disease PBSC. Presenter: Dr Liga Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: An overview of the haplo PTCY platform. Presenter: Dr Liga. Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr Triantafyllou.

Goal: Principles of Donor selection. Quiz and examples were shown. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Triantafyllou